https://www.selleckchem.com/pr....oducts/plerixafor.ht
4% and 28.4%, respectively. The median overall survival (OS) time was 12.6 months. Tumor response to first-line therapy was related to patient prognosis. New drugs may be beneficial for patients with advanced STS. When patients cannot receive anthracycline-based chemotherapy because of a high risk of side effects, we believe that the aforementioned drugs may be administered as the first-line treatment. New drugs may be beneficial for patients with advanced STS. When patients cannot receive anthracycline-based chemotherapy because of
Like
Comment
Share
